Latest quarter
Ecolab reported Q3 FY2026 revenue of $4.7 billion, up from $4.2 billion a year earlier and 0.49% above the consensus. Adjusted earnings of $2.18 per share matched the consensus.
The filing shows organic sales rose 7%, with Global Water up 9% as High-Tech, Food & Beverage and Light Water accelerated. Global Pest Elimination grew 8%, while Life Sciences grew 17%, helped by bioprocessing, pharmaceuticals and personal care, and purification. Institutional & Specialty grew 3% organically.
Ecolab’s gross margin fell to 44.1% from 44.8%, and operating margin declined to 17.3% from 18.3%. The filing says pricing offset higher commodity costs on an organic gross-margin basis, while acquisition financing increased net interest expense to $124.8 million from $55.3 million a year earlier.
The filing reports diluted EPS of $1.95, down 5%, and adjusted diluted EPS of $2.18, up 5%. Ecolab’s quarterly free cash flow was $450.6 million, down from $533.7 million a year earlier.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $4.7 billion | $4.2 billion | 12.7% |
| Diluted EPS | $1.97 | $2.05 | −4.13% |
| Gross margin | 44.1% | 44.8% | −0.7 percentage points |
| Operating margin | 17.3% | 18.3% | −1.0 percentage point |
| Free cash flow | $450.6 million | $533.7 million | −15.6% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.18 | $2.18 | In line |
| Revenue | $4.7 billion | $4.7 billion | In line |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO Christophe Beck said Ecolab’s core businesses strengthened and its growth engines accelerated during the quarter. In High-Tech, he attributed demand to data-center cooling and circular water for microelectronics; in Life Sciences, he said bioprocessing led growth as customers moved drug molecules into commercial manufacturing.
Beck said commodity costs were expected to remain high, but pricing and supply-chain management should continue to offset them. Organic operating income margin reached 19.6% in the quarter, which he linked to productivity and investments in the One Ecolab initiative.
For Institutional & Specialty, Beck pointed to declining North American restaurant traffic and said Ecolab would expand its field sales presence, integrate service across customer segments and combine more of its water, hygiene and pest offerings. He said the company planned to double its North American sales capacity in the business.
Asked about High-Tech, Beck said Ecolab had integrated its data-center business with CoolIT and its microelectronics business with Ovivo. He said the current growth was not driven by cross-selling between those businesses, which he described as an opportunity ahead. On competition, he said Ecolab was offering integrated cooling rather than individual components.
Beck also said the company would expand manufacturing capacity for cooling equipment and related technology, both in Calgary and closer to customers. Asked about revenue potential per megawatt installed, he said the company was still working out a total for its data-center offering.
On the pace of High-Tech growth, Beck cautioned that “63% is not going to be the steady state growth that we’re planning.” For Life Sciences, he said the prior-year maintenance comparison had helped quarterly earnings growth and that the same pace would not continue in coming quarters.
Guidance
For full-year 2026, Ecolab now expects adjusted earnings of $8.10 to $8.20 per share, compared with its previous outlook of $8.05 to $8.25 per share.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| EPS growth, non-GAAP | Q4 FY2026 | −$0.12 | — | New |
| Operating margin, Life Sciences | Q4 FY2026 | Ecolab expects Life Sciences operating margin to be in the mid- to high-teens in Q4 FY2026. | — | — |
| EPS growth, non-GAAP | FY2027 | $0.12–$0.15 | — | New |
| Operating margin, non-GAAP | FY2027 | 20.0% | — | New |
| Revenue growth, Organic | FY2027 | 7.00% | — | New |
| Operating margin, Global High Tech | FY2030 | 25.0% | 25.0% | Held |
| Revenue, Global High Tech | FY2030 | $4.0 billion | $4.0 billion | Held |
| Revenue growth, Global High Tech | FY2030 | 25.0% | — | New |
| Operating margin, Organic | H2 FY2026 | 20.0% | — | New |
| Operating margin, non-GAAP | H2 FY2026 | 19.0% | — | New |
| Revenue growth, Organic | H2 FY2026 | 6.00%–7.00% | — | New |
| Revenue growth, Reported | H2 FY2026 | 12.0%–14.0% | — | New |
| Operating margin, Global high-tech | FY2030 | 25.0% | — | New |
| Revenue, Global high-tech | FY2030 | $4.0 billion | — | New |
| Revenue, Ovivo electronics | FY2026 | Ecolab expects Ovivo Electronics to grow mid-teens in FY2026 versus pre-acquisition sales. | — | — |
| EPS, non-GAAP | FY2026 | $8.05–$8.25 | — | New |
| Capex growth | Next couple of years | 7.00% | — | New |
| Units, Pest Intelligence | FY2026 | 1,000,000 | — | — |
| Operating margin, Life Sciences | Long term | 30.0% | — | New |
| Revenue growth, Life Sciences | Long term | 10.0%–12.0% | — | New |
| Revenue growth, Global High Tech | through FY2030 | 25.0% | — | New |
| Revenue growth, Growth Engines | FY2027 | 25.0% | — | New |
| Operating margin | Long term | 20.0% | — | New |
| Revenue growth | Long term | 5.00%–7.00% | — | New |
| EPS growth | Long term | $0.12–$0.15 | — | New |
| Operating margin | FY2027 | 20.0% | — | New |
| EPS growth | FY2026 | $0.07–$0.10 | — | New |
| Operating margin | H2 2026 | 19.0% | — | New |
| Revenue growth | H2 2026 | 6.00%–7.00% | — | New |